Exponent, Inc. — FY2021 Form 10-K Summary
Reporting-period note: The request metadata says “2020 Q4,” but the supplied filing is Exponent’s Form 10-K for the fiscal year ended December 31, 2021 (52 weeks). It does not provide a clear standalone fourth-quarter income statement.
Business context
Exponent provides scientific and engineering consulting through two reportable segments: Engineering and Other Scientific, and Environmental and Health. Its project-based work includes failure analysis, litigation support, product safety, regulatory consulting, and proactive risk assessment. The business is labor-intensive, and engagements can be postponed or terminated by clients; management says backlog is not a reliable indicator of future revenue.
Financial performance and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $466.3 million | $399.9 million | +16.6% |
| Revenue before reimbursements | $434.9 million | $378.4 million | +14.9% |
| Operating income | $108.9 million | $83.2 million | +30.8% |
| Net income | $101.2 million | $82.6 million | +22.6% |
| Diluted EPS | $1.90 | $1.55 | — |
| Operating margin | 23.4% | 20.8% | +2.6 percentage points |
| Net margin | 21.7% | 20.6% | +1.1 percentage points |
| Operating cash flow | $124.6 million | $103.3 million | +20.6% |
Cash and cash equivalents were $297.7 million at year-end, compared with $197.5 million; the prior-year balance also included $45.0 million of short-term investments. Current assets were $452.8 million and current liabilities $153.0 million. The balance sheet reports no borrowings or other debt. Capital expenditures were $6.8 million. Cash used for dividends was $43.2 million and for share repurchases was $7.0 million.
EBITDA was $132.3 million, or 30.4% of revenue before reimbursements, versus $102.1 million and 27.0% in FY2020; these are non-GAAP measures. The effective tax rate rose to 19.6% from 14.8%, primarily reflecting a smaller excess tax benefit from stock-based awards. Excluding that benefit, management reported an effective tax rate of 27.5% in both years.
Material changes versus FY2020
- Revenue growth reflected higher billable hours and billing rates. Billable hours increased 10% overall, while utilization rose to 75% from 67%.
- Engineering and Other Scientific revenue grew 19.3% to $380.9 million; Environmental and Health revenue grew 6.0% to $85.4 million.
- Operating margin improved as revenue growth outpaced compensation and other operating expense growth. Compensation expense rose 11.2%; reimbursable expenses rose 46.2% as project travel and other costs recovered.
- One client represented 13% of FY2021 revenue; no client exceeded 10% in FY2020 or FY2019. Consumer products, energy and utilities, transportation, and chemicals represented approximately 28%, 15%, 13%, and 11% of FY2021 revenue, respectively.
- The company repurchased 78,000 shares for $7.0 million, down from 636,000 shares for $40.0 million in FY2020. Dividends declared rose to $0.80 per share from $0.76.
Outlook, risks, and unusual items
Management gave no numerical revenue or earnings guidance. It cited strong demand in utilities, consumer electronics, consumer products, life sciences, and automotive, as well as human-factors and machine-learning studies, battery-related work, and recovery in litigation-related services. Management expects compensation costs to rise with selective hiring and market-based pay adjustments, and expects other operating and general and administrative expenses to increase as hiring, infrastructure investment, business development, and office-based work expand.
Key disclosed risks include lingering COVID-19 effects on project timing, travel, client operations, and recruiting; unpredictable engagement timing and limited backlog; competition and pricing pressure; difficulty attracting and retaining specialized staff; client nonpayment; reliance on professional reputation; litigation and professional liability; data security and privacy; and foreign-currency and international operating risks. A downturn, reduced regulatory enforcement, or tort reform could also weaken demand.
Management said available cash and operating cash flows should meet working-capital, capital, dividend, and repurchase needs for at least 12 months. Operating lease obligations totaled $16.8 million in undiscounted payments. The company reported no material legal proceedings, while noting ordinary-course claims and contingencies. Deferred compensation plan assets and liabilities were approximately $109.3 million and $110.4 million, respectively; changes in plan investment values increased both other income and compensation expense. The auditor identified collectibility of receivables as a critical audit matter; the allowance for contract losses and doubtful accounts was $4.4 million. KPMG gave an unqualified opinion and reported effective internal control over financial reporting.
Subsequent to year-end, the board authorized an additional $150 million share-repurchase program and declared a $0.24-per-share quarterly dividend payable in March 2022. These are post-period actions, not FY2021 results.
Important facts for investors to verify
- Confirm the intended period: the supplied filing covers FY2021, not 2020 Q4, and contains no clear standalone Q4 results.
- Review whether revenue growth and utilization gains persist, given project timing variability and the lack of a meaningful backlog.
- Assess receivable quality and collection risk: net receivables were $139.9 million, and the auditor focused on collectibility.
- Track client concentration, particularly the client contributing 13% of FY2021 revenue, and the company’s exposure to its largest industry sectors.
- Consider the effect of stock-based tax benefits and deferred-compensation investment gains when evaluating earnings quality and comparability.
- Verify future hiring, expense growth, dividends, and repurchases against cash generation; the filing cautions that dividends and buybacks are not assured at any particular level.